Identification of oncogenes from myeloid leukaemias by retroviral expression cloning

Funded Activity Summary

The success rates for treatment of most myeloid leukaemias remain relatively poor, with 5-year survival rates of 40-50% overall. Thus there is a clear need for improvements in diagnosis and particularly treatment. An important and relatively new approach for doing this is to target the specific molecular and genetic alterations that lead to these diseases. This requires the identification of these alterations, particularly the oncogenes ('cancer genes') that cause or contribute to the various forms of myeloid leukaemia. However in many cases (up to 50%), the key oncogenes involved in have not and-or cannot be identified using current methods. This project aims to develop and apply a powerful technique called 'retroviral expression cloning' for the identification of oncogenes involved in myeloid leukaemia. In essence our approach is to identify oncogenes from myeloid leukaemia samples on the basis of their function - that is, by virtue of their ability to induce dysregulated or uncontrolled growth of blood-derived cells in culture.

Funded Activity Details

Start Date: 01-01-2005

End Date: 01-01-2007

Funding Scheme: NHMRC Project Grants

Funding Amount: $552,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology and Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug target | growth factor | leukaemia | monocyte/macrophage differentiation | myeloid leukaemia | myeloproliferative disorders of the haemopoietic system | oncogene | retroviral gene transfer

Related Links